Speed up the Development of and Access to Innovative Medical Countermeasures (Бельгия - Тендер #43820636)

Speed up the Development of and Access to Innovative Medical Countermeasures

The subject of this call for tenders is to conclude service contracts for the purchasing of clinical and non-clinical services to speed up availability and access to innovative medical countermeasures (MCMs). The innovative MCMs include promising solutions that are indicated to diagnose/detect, prevent, protect from or treat conditions associated to serious cross border health threats.

Vaccines to Combat Antimicrobial Resistance

The services will be performed at the contractor’s premises or, for the purposes of the activities required (e.g. organisation of meetings) at any other location agreed with the contracting authority.

This lot will support the assessment of the candidate’s efficacy and further assessment of safety (within Phase II clinical trials), as well as any development that helps identify the most promising preparation, dose, and schedule to be tested in Phase III clinical trials.

Broad Spectrum Antivirals Targeting Respiratory RNA Viral Families

The services will be performed at the contractor’s premises or, for the purposes of the activities required (e.g. organisation of meetings) at any other location agreed with the contracting authority.

This lot foresees support to obtain partial information on drug efficacy, namely ‘Phase IIb’ clinical trials, for contexts where viral diseases occur with relevant incidence. When relevant and duly justified (e.g., lack of commercial interest or another type of market failure that leads to crowding out investments and partnerships), tenderers may also apply for partial support for the assessment of a primary efficacy endpoint of Phase III trials, specifying the measure of the disease-related outcome of public health interest, such as mortality or disease morbidity, that supports the antiviral candidate indication for use.

Broad Spectrum Antivirals – Viral-haemorrhagic Fevers

The services will be performed at the contractor’s premises or, for the purposes of the activities required (e.g. organisation of meetings) at any other location agreed with the contracting authority.

This lot foresees support to obtain partial information on drug efficacy, namely ‘Phase IIb’ clinical trials, for contexts where viral diseases occur with relevant incidence. When relevant and duly justified (e.g., lack of commercial interest or another type of market failure that leads to crowding out investments and partnerships), tenderers may also apply for partial support for the assessment of a primary efficacy endpoint of Phase III trials, specifying the measure of the disease-related outcome of public health interest, such as mortality or disease morbidity, that supports the antiviral candidate indication for use.

Point of Care Metagenomic Sequencing for Universal Pathogen Detection

The services will be performed at the contractor’s premises or, for the purposes of the activities required (e.g. organisation of meetings) at any other location agreed with the contracting authority.

This lot supports the development of a metagenomic next-generation sequencing (mNGS)-based test that can detect any respiratory viral pathogen, including novel and emerging, from any human respiratory sample type.

This prior information notice announces the intention of the contracting authority to publish a future call for tenders. No other information or documents are available at this stage. Interested economic operators are invited to subscribe at the address in Section I.3) in order to get notified when the contract notice and all the procurement documents, including the tender specifications, are published.